<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753804</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-DMD-01</org_study_id>
    <nct_id>NCT01753804</nct_id>
  </id_info>
  <brief_title>A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.</brief_title>
  <official_title>A Prospective Natural History Study of Progression of Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prosensa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prosensa Therapeutics</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to
      help inform the design of future studies, to capture biomarkers of safety and disease
      progression and to provide comparative data for the development of rare exons for which
      formal controlled trials are not feasible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study.  All DMD patients that fulfil the inclusion/exclusion criteria
      are eligible although the study is weighted towards ambulant subjects aged 3 years or older.
       There will be 7 study visits and subjects will be in the study for a maximum of 3 years.
      Visits will occur every 6  months (+/- 1 month).

      Up to 250 DMD subjects planned in the following categories :

        -  75 % ambulant subjects aged between 3 and 18 years at study entry

        -  25% non-ambulant subjects with a maximum age of 18 years at study entry

      Subjects will be asked to perform muscle testing assessment with a clinical evaluator, such
      as walking for 6 minutes, climb stairs, breathe in a tube, see how they can move their arms
      and legs. They will be asked questions about how they feel overall and perform daily
      activities. These measurements will be assessed every 6 months.

      Urine and blood samples will be collected once a year to measure biomarkers that will allow
      to have a better overview of DMD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>Change from visit 1 walking distance</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants are asked to walk at their own preferred speed on a fixed distance for 6 minutes. Subjects are warned of the time and that they may stop earlier if they feel unable to continue. Total distance walked within 6 minutes (or until stopping) is recorded.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Study participants</arm_group_label>
    <description>All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>There is no medication or device tested in this study. This is an obversational study on the progression of the disease.</description>
    <arm_group_label>Study participants</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling at 4 time points (first visit then once a year). Urinalysis sampling at 4
      time points (first visit then once a year).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with DMD resulting from a mutation in the DMD gene which is confirmed
        by a state of the art DNA diagnostic technique covering all DMD gene exons
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of DMD resulting from a mutation in the DMD gene confirmed by a state of
             the art DNA diagnostic technique covering all DMD gene exons.

          -  Age 3 - 18 years

          -  Willing and able to comply with protocol requirements

          -  Life expectancy of at least 3 years

          -  Able to give informed assent and/or consent in writing signed by the subject and/or
             parent(s)/legal guardian (according to local regulations)

        Exclusion Criteria:

          -  Current participation in a clinical study with an Investigational Medicinal Product
             (IMP)

          -  Participation within the previous 1 month in a clinical study with an IMP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Goemans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Info Prosensa</last_name>
    <email>patientinfo@prosensa.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goude</last_name>
      <phone>916-734-0968</phone>
      <email>erica.goude@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Henricson, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Jacobson, MS</last_name>
      <phone>513-803-9036</phone>
      <email>sarah.jacobson@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gailey</last_name>
      <phone>614-355-2897</phone>
      <email>susan.gailey@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Krista Kunkler</last_name>
      <phone>614-722-2238</phone>
      <email>krista.kunkler@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Pediatria Prof Dr Juan P Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliana Cavassa</last_name>
    </contact>
    <investigator>
      <last_name>Soledad Monges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernanda De Castro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lien Everaert</last_name>
      <phone>+3293321954</phone>
      <email>Lien.Everaert@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Nicolas DeConinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corine Antonis</last_name>
      <phone>+3216343845</phone>
      <email>corine.antonis@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Vivona</last_name>
      <email>dovivona@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Bernadete Dutra Resende, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hopital des enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Auriol</last_name>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Cances, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Giagkou</last_name>
      <email>eleni.giagkou@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Wein</last_name>
      <phone>+4976127044740</phone>
      <email>ursula.wein@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Jan-Bernd Kirschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Boettler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Messina, MD</last_name>
      <phone>+390902217178</phone>
      <email>smessina@unime.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Univsersitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marika Pane</last_name>
      <email>marika.pane@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Mosselman</last_name>
      <email>M.H.Mosselman-van_Joolingen@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Zaida Koeks</last_name>
      <email>z.koeks@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Niks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrie Erasmus</last_name>
      <email>c.erasmus@neuro.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Lilian Sie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn- ochungdomssjukhus</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrika Sterky</last_name>
      <phone>+46 31 3438207</phone>
      <email>ulrika.sterky@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mar Tulinius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayse Karaduman</last_name>
      <email>aykaradu@hacettepe.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Haluk Topaloglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.prosensa.eu/home</url>
    <description>Prosensa Therapeutics website</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>December 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Myopathy</keyword>
  <keyword>Natural History</keyword>
  <keyword>Muscular dystrophy</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Muscle testing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
